Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone

被引：20

作者：

Morgan, Gareth ^{[1
]}

Palumbo, Antonio ^{[2
]}

Dhanasiri, Sujith ^{[3
]}

Lee, Dawn ^{[4
]}

Weisel, Katja ^{[5
]}

Facon, Thierry ^{[6
]}

Delforge, Michel ^{[7
]}

Oriol, Albert ^{[8
]}

Zaki, Mohamed ^{[9
]}

Yu, Xin ^{[9
]}

Sternas, Lars ^{[9
]}

Jacques, Christian ^{[9
]}

Akehurst, Ron ^{[4
,10
]}

Offner, Fritz ^{[11
]}

Dimopoulos, Meletios A. ^{[12
]}

机构：

[1] Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Little Rock, AR 72205 USA

[2] Via Univ Torino, Turin, Italy

[3] Celgene Ltd, London, England

[4] Bres Med, Sheffield, S Yorkshire, England

[5] Univ Tubingen, Tubingen, Germany

[6] CHU Lille, Serv Malad Sang, F-59037 Lille, France

[7] Univ Hosp Leuven, Leuven, Belgium

[8] Hosp Badalona Germans Trias & Pujol, Barcelona, Spain

[9] Celgene Corp, Summit, NJ USA

[10] Univ Sheffield, Sheffield, S Yorkshire, England

[11] Univ Ziekenhuis Gent, Ghent, Belgium

[12] Univ Athens, Alexandra Hosp, Sch Med, Athens 11528, Greece

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2015年 / 168卷 / 06期

关键词：

multiple myeloma; pomalidomide; survival; crossover; bias;

D O I：

10.1111/bjh.13227

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In the phase III MM-003 trial, pomalidomide plus low-dose dexamethasone (POM+LoDEX) improved overall survival (OS) versus high-dose dexamethasone (HiDEX) in 455 patients with relapsed and refractory multiple myeloma (RRMM) after treatment with bortezomib and lenalidomide. Here, a two-stage Weibull method was used to adjust for the crossover of patients in the HiDEX arm to pomalidomide-based therapy. The adjusted difference in median OS between patients in the POM+LoDEX and HiDEX arms was 70months (127 vs. 57months, respectively). These findings provide important evidence for understanding the clinical efficacy of pomalidomide on OS benefits seen in RRMM patients.

引用

页码：820 / 823

页数：4

共 50 条

[31] MM-008: A Phase 1 Trial Evaluating Pharmacokinetics and Tolerability of Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed or Refractory and Refractory Multiple Myeloma and Renal Impairment
Matous, Jeffrey
Siegel, David S.
Lonial, Sagar
Harvey, R. Donald
Kasserra, Claudia
Li, Yan
Chen, Min
Doerr, Thomas
Sternas, Lars
Zaki, Mohamed H.
Jacques, Christian
Shah, Jatin J.
[J]. BLOOD, 2014, 124 (21)
[32] Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
Dimopoulos, Meletios A.
Weisel, Katja C.
Song, Kevin W.
Delforge, Michel
Karlin, Lionel
Goldschmidt, Hartmut
Moreau, Philippe
Banos, Anne
Oriol, Albert
Garderet, Laurent
Cavo, Michele
Ivanova, Valentina
Alegre, Adrian
Martinez-Lopez, Joaquin
Chen, Christine
Spencer, Andrew
Knop, Stefan
Bahlis, Nizar J.
Renner, Christoph
Yu, Xin
Hong, Kevin
Sternas, Lars
Jacques, Christian
Zaki, Mohamed H.
San Miguel, Jesus F.
[J]. HAEMATOLOGICA, 2015, 100 (10) : 1327 - 1333
[33] Pomalidomide plus Low-Dose Dexamethasone plus Daratumumab in Relapsed and/or Refractory Multiple Myeloma after Lenalidomide-Based Treatment Failure
Siegel, David S.
Schiller, Gary J.
Samaras, Christy J.
Sebag, Michael
Berdeja, Jesus G.
Ganguly, Siddhartha
Matous, Jeffrey V.
Song, Kevin
Seet, Christopher S.
Talamo, Giampaolo
Acosta-Rivera, Mirelis
Bar, Michael
Quick, Donald P.
Anz, Bertrand
Fonseca, Gustavo
Reece, Donna
Agarwal, Amit
Chung, Weiyuan
Zafar, Faiza
Bahlis, Nizar
[J]. BLOOD, 2018, 132
[34] MM-008: A Phase 1 Trial Evaluating Pharmacokinetics and Tolerability Of Pomalidomide plus Low-Dose Dexamethasone In Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment
Matous, Jeffrey
Siegel, David S.
Duong, Hien K.
Kasserra, Claudia
Chen, Min
Doerr, Thomas
Sternas, Lars
Zaki, Mohamed H.
Jacques, Christian
Shah, Jatin J.
[J]. BLOOD, 2013, 122 (21)
[35] Patient Outcomes By Prior Therapies and Depth of Response: Analysis of MM-003, a Phase 3 Study Comparing Pomalidomide plus Low-Dose Dexamethasone (POM plus LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM)
San Miguel, Jesus F.
Weisel, Katja
Song, Kevin W.
Delforge, Michel
Karlin, Lionel
Goldschmidt, Hartmut
Moreau, Philippe
Banos, Anne
Oriol, Albert
Garderet, Laurent
Cavo, Michele
Ivanova, Valentina
Alegre, Adrian
Martinez-Lopez, Joaquin
Chen, Christine I.
Renner, Christoph
Bahlis, Nizar J.
Yu, Xin
Teasdale, Terri
Sternas, Lars
Jacques, Christian
Zaki, Mohamed H.
Dimopoulos, Meletios A.
[J]. BLOOD, 2013, 122 (21)
[36] Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study
Richardson, Paul G.
Perrot, Aurore
San-Miguel, Jesus
Beksac, Meral
Spicka, Ivan
Leleu, Xavier
Schjesvold, Fredrik
Moreau, Philippe
Dimopoulos, Meletios A.
Huang, Jeffrey Shang-Yi
Minarik, Jiri
Cavo, Michele
Prince, H. Miles
Malinge, Laure
Dubin, Franck
van de Velde, Helgi
Anderson, Kenneth C.
[J]. LANCET ONCOLOGY, 2022, 23 (03): : 416 - 427
[37] Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
Attal, Michel
Richardson, Paul G.
Rajkumar, S. Vincent
San-Miguel, Jesus
Beksac, Meral
Spicka, Ivan
Leleu, Xavier
Schjesvold, Fredrik
Moreau, Philippe
Dimopoulos, Meletios A.
Huang, Jeffrey Shang-Yi
Minarik, Jiri
Cavo, Michele
Prince, H. Miles
Mace, Sandrine
Corzo, Kathryn P.
Campana, Frank
Le-Guennec, Solenn
Dubin, Franck
Anderson, Kenneth C.
[J]. LANCET, 2019, 394 (10214): : 2096 - 2107
[38] A POOLED ANALYSIS OF THE IMPACT OF AGE ON OUTCOMES IN PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA TREATED WITH POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE
Palumbo, A.
Dimopoulos, M. A.
Richardson, P. G.
Siegel, D. S.
Cavo, M.
Corradini, P.
Weisel, K. C.
Delforge, M.
Chen, C.
Goldschmidt, H.
Jagannath, S.
Lockhorst, H. M.
Moreau, P.
Plesner, T.
Sternas, L.
Peluso, T.
Hong, K.
Herring, J.
Yu, X.
Zaki, M. H.
San Miguel, J.
[J]. HAEMATOLOGICA, 2016, 101 : 535 - 536
[39] Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma
Bahlis, Nizar J.
Sutherland, Heather
White, Darrell
Sebag, Michael
Lentzsch, Suzanne
Kotb, Rami
Venner, Christopher P.
Gasparetto, Cristina
Del Col, Aldo
Neri, Paola
Reece, Donna
Kauffman, Michael
Shacham, Sharon
Unger, T. J.
Jeha, Jacqueline
Saint-Martin, Jean-Richard
Shah, Jatin
Chen, Christine
[J]. BLOOD, 2018, 132 (24) : 2546 - 2554
[40] MM-013 PHASE 2 MULTICENTER STUDY OF POMALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND RENAL IMPAIRMENT
Sonneveld, P.
Weisel, K.
van de Donk, N.
Ramasamy, K.
Gamberi, B.
Streetly, M.
Offidani, M.
Bridoux, F.
de la Rubia, J.
Kueenburg, E.
Collins, S.
Di Micco, A.
Rosettani, B.
Bacon, P.
Dimopoulos, M.
[J]. HAEMATOLOGICA, 2017, 102 : 113 - 114

← 1 2 3 4 5 →